Drugs / ALLN-346
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05168683 | Jan → Feb 2022 | gout | Allena Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT04829435 | Apr → Jun 2021 | gout | Allena Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT04236219 | Sep → Nov 2020 | — | Allena Pharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04987294 | Sep 2022 | chronic kidney disease, gout | Allena Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04987242 | Jul 2021 → Mar 2022 | chronic kidney disease, gout | Allena Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALLN-346 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04987242 ↗ |
| Action | Inhibit | “degrades urate in the gastrointestinal tract” NCT04236219 ↗ |
| Modality | Protein / enzyme biologic | “ALLN-346 is an enzyme” NCT04236219 ↗ |
| Route | Oral | “orally administered ALLN-346” NCT04236219 ↗ |